Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5% - Should You Sell?

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) shares traded down 5% during trading on Friday . The stock traded as low as $8.48 and last traded at $8.48. 147,052 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 815,927 shares. The stock had previously closed at $8.92.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Wall Street Zen upgraded shares of Eyepoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Royal Bank Of Canada assumed coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday. They set an "outperform" rating and a $28.00 target price for the company. Mizuho lowered their target price on shares of Eyepoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research note on Friday, May 16th. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of Eyepoint Pharmaceuticals in a research report on Thursday, May 29th. Finally, Chardan Capital decreased their price objective on Eyepoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.67.

Eyepoint Pharmaceuticals Stock Down 5.4%

The firm has a 50 day moving average price of $6.89 and a 200-day moving average price of $6.93. The stock has a market capitalization of $580.76 million, a PE ratio of -3.49 and a beta of 1.61.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.65) EPS for the quarter, meeting the consensus estimate of ($0.65). The company had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. Eyepoint Pharmaceuticals had a negative net margin of 261.91% and a negative return on equity of 54.27%. Equities analysts expect that Eyepoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of EYPT. Summit Investment Advisors Inc. lifted its stake in shares of Eyepoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after purchasing an additional 1,940 shares during the period. KLP Kapitalforvaltning AS purchased a new position in Eyepoint Pharmaceuticals in the fourth quarter valued at $59,000. Virtus ETF Advisers LLC acquired a new position in shares of Eyepoint Pharmaceuticals in the fourth quarter worth about $67,000. AlphaQuest LLC grew its position in shares of Eyepoint Pharmaceuticals by 13,246.6% during the 4th quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock valued at $73,000 after acquiring an additional 9,670 shares during the period. Finally, Raymond James Financial Inc. purchased a new position in Eyepoint Pharmaceuticals during the fourth quarter worth approximately $76,000. 99.41% of the stock is owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.